ATE353906T1 - Cd27 ligand - Google Patents
Cd27 ligandInfo
- Publication number
- ATE353906T1 ATE353906T1 AT93920446T AT93920446T ATE353906T1 AT E353906 T1 ATE353906 T1 AT E353906T1 AT 93920446 T AT93920446 T AT 93920446T AT 93920446 T AT93920446 T AT 93920446T AT E353906 T1 ATE353906 T1 AT E353906T1
- Authority
- AT
- Austria
- Prior art keywords
- cd27l
- ligand
- polypeptide
- vectors
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/14—Lymphokine; related peptides
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94164892A | 1992-09-08 | 1992-09-08 | |
US08/106,507 US5573924A (en) | 1992-09-08 | 1993-08-13 | CD27 ligand |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE353906T1 true ATE353906T1 (de) | 2007-03-15 |
Family
ID=26803747
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT93920446T ATE353906T1 (de) | 1992-09-08 | 1993-09-01 | Cd27 ligand |
Country Status (9)
Country | Link |
---|---|
US (1) | US5573924A (de) |
EP (1) | EP0662077B1 (de) |
JP (1) | JP3559281B2 (de) |
AT (1) | ATE353906T1 (de) |
AU (1) | AU5099293A (de) |
CA (1) | CA2144056C (de) |
DE (1) | DE69334111T2 (de) |
ES (1) | ES2281896T3 (de) |
WO (1) | WO1994005691A1 (de) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7405270B2 (en) * | 1991-10-25 | 2008-07-29 | Immunex Corporation | CD40-Ligand lacking native-pattern glycosylation |
US5573924A (en) | 1992-09-08 | 1996-11-12 | Immunex Corporation | CD27 ligand |
US6599719B2 (en) | 1994-11-07 | 2003-07-29 | Human Genome Sciences, Inc. | Nucleic acid molecules encoding tumor necrosis factor-gamma-alpha |
US6824767B2 (en) | 1994-11-07 | 2004-11-30 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
US5994503A (en) * | 1995-03-27 | 1999-11-30 | Yale University | Nucleotide and protein sequences of lats genes and methods based thereon |
US7070771B1 (en) | 1996-12-09 | 2006-07-04 | Regents Of The University Of California | Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells |
US6010853A (en) * | 1997-05-29 | 2000-01-04 | Dana-Farber Cancer Institute | Siva genes, novel genes involved in CD27-mediated apoptosis |
US6307024B1 (en) * | 1999-03-09 | 2001-10-23 | Zymogenetics, Inc. | Cytokine zalpha11 Ligand |
US7034132B2 (en) | 2001-06-04 | 2006-04-25 | Anderson David W | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
WO2003009862A1 (en) * | 2001-07-20 | 2003-02-06 | Genset S.A. | Agonists and antagonists of modumet for use in the treatment of metabolic disorders |
US7261892B2 (en) * | 2001-11-27 | 2007-08-28 | Celltech R&D Limited | Methods for diagnosis and treatment of epithelial-derived cancers |
WO2003046581A2 (en) * | 2001-11-27 | 2003-06-05 | Oxford Glycosciences (Uk) Ltd | Methods for diagnosis and treatment of epithelial-derived cancers,such as colorectal cancers and kidney cancers |
US7786282B2 (en) * | 2001-12-06 | 2010-08-31 | The Regents Of The University Of California | Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain |
EP1576088A4 (de) * | 2002-01-04 | 2006-09-06 | Xencor Inc | Dominant-negative proteine und verfahren dazu |
US20040170602A1 (en) * | 2002-01-04 | 2004-09-02 | Desjarlais John R. | Dominant negative proteins and methods thereof |
SG108837A1 (en) * | 2002-03-11 | 2005-02-28 | Pi Eta Consulting Co Pte Ltd | An enterprise knowledge and information acquisition, management and communications system with intelligent user interfaces |
US20040223966A1 (en) * | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
US20080025989A1 (en) * | 2003-02-20 | 2008-01-31 | Seattle Genetics, Inc. | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
JP5356648B2 (ja) * | 2003-02-20 | 2013-12-04 | シアトル ジェネティックス, インコーポレイテッド | 抗cd70抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用 |
US20050282168A1 (en) * | 2003-09-29 | 2005-12-22 | Wyeth | Cell surface molecules as markers and therapeutic agents against kidney cancers |
US7641903B2 (en) * | 2004-10-15 | 2010-01-05 | Seattle Genetics, Inc. | Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders |
US8337838B2 (en) * | 2004-10-15 | 2012-12-25 | Seattle Genetics, Inc. | Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders |
US7491390B2 (en) * | 2004-10-15 | 2009-02-17 | Seattle Genetics, Inc. | Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders |
EP1871418B1 (de) | 2005-04-19 | 2014-03-19 | Seattle Genetics, Inc. | Humanisierte, anti-cd70-bindende wirkstoffe und ihre verwendung |
US8124738B2 (en) * | 2005-09-26 | 2012-02-28 | Medarex, Inc. | Human monoclonal antibodies to CD70 |
AU2007333098A1 (en) * | 2006-12-14 | 2008-06-19 | Medarex, Inc. | Human antibodies that bind CD70 and uses thereof |
EP2090320A1 (de) | 2008-02-15 | 2009-08-19 | Helmholtz-Zentrum für Infektionsforschung GmbH | Liganden des natürlichen Killer Zelloberflächenmarkers CD27 und therapeutische Verwendungen davon |
ES2458541T3 (es) | 2008-05-02 | 2014-05-06 | Seattle Genetics, Inc. | Métodos y composiciones para elaborar anticuerpos y derivados de anticuerpos con fucosilación del núcleo reducida |
ES2571879T3 (es) * | 2008-07-21 | 2016-05-27 | Apogenix Ag | Moléculas de una sola cadena de TNFSF |
EP4190149A1 (de) | 2009-12-25 | 2023-06-07 | Chugai Seiyaku Kabushiki Kaisha | Verfahren zum suchen und screening auf ein ziel eines krebsmittels mit einem nichtmenschlichen tiermodell mit darin transplantierter nog-krebszelllinie |
WO2012046797A1 (ja) | 2010-10-06 | 2012-04-12 | ファーマロジカルズ・リサーチ プライベート リミテッド | 癌幹細胞集団及びその作製方法 |
CA2828753C (en) | 2011-03-16 | 2022-07-26 | arGEN-X BV | Antibodies to cd70 |
WO2013035824A1 (ja) | 2011-09-07 | 2013-03-14 | ファーマロジカルズ・リサーチ プライベート リミテッド | 癌幹細胞の分離 |
EP2758437B1 (de) * | 2011-09-22 | 2020-06-03 | Amgen Inc. | Cd27l-antigen-bindende proteine |
EP3603671A3 (de) | 2011-10-28 | 2020-07-29 | Chugai Seiyaku Kabushiki Kaisha | Krebstammzellenspezifisches molekül |
KR102153374B1 (ko) | 2012-03-15 | 2020-09-10 | 얀센 바이오테크 인코포레이티드 | 인간 항-cd27 항체, 방법 및 용도 |
US10391168B1 (en) | 2014-08-22 | 2019-08-27 | University Of Bern | Anti-CD70 combination therapy |
EP3858388A1 (de) | 2015-09-28 | 2021-08-04 | Regents of the University of Minnesota | T-zellen mit chimärem antigenrezeptor (car) als therapeutische eingriffe bei auto- und allo-immunität |
CA3002602C (en) * | 2015-10-23 | 2021-11-02 | Apogenix Ag | Single-chain cd27-receptor agonist proteins |
GB201800649D0 (en) | 2018-01-16 | 2018-02-28 | Argenx Bvba | CD70 Combination Therapy |
TW202038958A (zh) | 2018-12-18 | 2020-11-01 | 比利時商阿根思公司 | Cd70組合治療 |
TW202138388A (zh) | 2019-12-30 | 2021-10-16 | 美商西根公司 | 以非海藻糖苷化抗-cd70抗體治療癌症之方法 |
CN116997654A (zh) | 2021-03-17 | 2023-11-03 | 第一三共株式会社 | 编码抗乙酰胆碱受体自身抗体的嵌合受体的基因 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5573924A (en) | 1992-09-08 | 1996-11-12 | Immunex Corporation | CD27 ligand |
ES2198414T3 (es) * | 1992-10-23 | 2004-02-01 | Immunex Corporation | Procedimientos para preparar proteinas oligomericas solubles. |
-
1993
- 1993-08-13 US US08/106,507 patent/US5573924A/en not_active Expired - Lifetime
- 1993-09-01 EP EP93920446A patent/EP0662077B1/de not_active Expired - Lifetime
- 1993-09-01 JP JP50741194A patent/JP3559281B2/ja not_active Expired - Lifetime
- 1993-09-01 ES ES93920446T patent/ES2281896T3/es not_active Expired - Lifetime
- 1993-09-01 AT AT93920446T patent/ATE353906T1/de not_active IP Right Cessation
- 1993-09-01 CA CA2144056A patent/CA2144056C/en not_active Expired - Lifetime
- 1993-09-01 WO PCT/US1993/008223 patent/WO1994005691A1/en active IP Right Grant
- 1993-09-01 DE DE69334111T patent/DE69334111T2/de not_active Expired - Lifetime
- 1993-09-01 AU AU50992/93A patent/AU5099293A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JPH08500976A (ja) | 1996-02-06 |
EP0662077A4 (de) | 1997-01-08 |
CA2144056A1 (en) | 1994-03-17 |
DE69334111T2 (de) | 2007-11-22 |
WO1994005691A1 (en) | 1994-03-17 |
EP0662077A1 (de) | 1995-07-12 |
DE69334111D1 (en) | 2007-03-29 |
JP3559281B2 (ja) | 2004-08-25 |
CA2144056C (en) | 2010-04-13 |
EP0662077B1 (de) | 2007-02-14 |
AU5099293A (en) | 1994-03-29 |
US5573924A (en) | 1996-11-12 |
ES2281896T3 (es) | 2007-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE353906T1 (de) | Cd27 ligand | |
DE69334100D1 (de) | Elk ligand, ein cytokin | |
DE69433552D1 (de) | An den zelloberflächenrezeptor hek bindendes cytokin | |
EP0770088A4 (de) | Cytokinin-designiertes lerk-5 | |
EP0871702A4 (de) | Cytokin lerk-7 | |
HK1013847A1 (en) | Gdf-1 and uog-1 proteins | |
EP1676857A3 (de) | Trail bindender Rezeptor | |
ZA967562B (en) | Materials and methods relating to the attachment and display of substances on cell surfaces. | |
DE69737978D1 (de) | Als 2f1 bezeichnetes rezeptorprotein | |
ATE257858T1 (de) | Cd40l mutein | |
IL132496A0 (en) | Mammalian cytokine-like factor 7 | |
EP0739350A4 (de) | Fas-antigenbindender ligand | |
MX9700213A (es) | Citocina novedosa designada como lerk-5. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |